GTS Securities LLC Has $348,000 Position in Kenvue Inc. (NYSE:KVUE)

GTS Securities LLC lessened its position in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 81.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 16,290 shares of the company's stock after selling 72,846 shares during the period. GTS Securities LLC's holdings in Kenvue were worth $348,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also made changes to their positions in the company. Norges Bank bought a new position in Kenvue in the fourth quarter valued at about $521,348,000. Starboard Value LP acquired a new stake in shares of Kenvue in the 4th quarter valued at approximately $467,864,000. Franklin Resources Inc. boosted its stake in shares of Kenvue by 61.5% in the 4th quarter. Franklin Resources Inc. now owns 42,719,377 shares of the company's stock valued at $912,059,000 after purchasing an additional 16,269,721 shares in the last quarter. Massachusetts Financial Services Co. MA grew its holdings in shares of Kenvue by 12.3% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 97,661,344 shares of the company's stock valued at $2,085,070,000 after purchasing an additional 10,682,003 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD grew its holdings in shares of Kenvue by 3.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 245,885,918 shares of the company's stock valued at $5,249,665,000 after purchasing an additional 8,211,748 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company's stock.

Kenvue Trading Down 0.9%

NYSE KVUE traded down $0.21 on Monday, reaching $23.67. The company had a trading volume of 9,774,685 shares, compared to its average volume of 16,319,737. The firm has a market cap of $45.41 billion, a price-to-earnings ratio of 44.65, a P/E/G ratio of 2.62 and a beta of 1.02. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69. Kenvue Inc. has a fifty-two week low of $17.67 and a fifty-two week high of $25.17. The business has a 50 day moving average of $23.28 and a two-hundred day moving average of $22.63.

Kenvue (NYSE:KVUE - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported $0.24 EPS for the quarter, beating analysts' consensus estimates of $0.23 by $0.01. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. The business had revenue of $3.74 billion for the quarter, compared to analysts' expectations of $3.69 billion. During the same quarter in the prior year, the firm posted $0.28 earnings per share. The business's quarterly revenue was down 3.9% compared to the same quarter last year. Analysts forecast that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, May 28th. Investors of record on Wednesday, May 14th were paid a dividend of $0.205 per share. The ex-dividend date was Wednesday, May 14th. This represents a $0.82 annualized dividend and a yield of 3.47%. Kenvue's dividend payout ratio is currently 149.09%.

Analyst Ratings Changes

Several equities analysts recently commented on KVUE shares. Piper Sandler increased their price objective on shares of Kenvue from $24.00 to $27.00 and gave the company an "overweight" rating in a research note on Monday, February 24th. Evercore ISI started coverage on Kenvue in a research note on Monday, March 24th. They issued an "in-line" rating and a $25.00 price target for the company. Canaccord Genuity Group raised their price objective on Kenvue from $24.00 to $29.00 and gave the company a "buy" rating in a report on Wednesday, March 5th. Royal Bank of Canada restated a "sector perform" rating and set a $24.00 price objective on shares of Kenvue in a research report on Monday, February 3rd. Finally, UBS Group upped their target price on Kenvue from $24.00 to $25.00 and gave the stock a "neutral" rating in a report on Friday, May 9th. Seven equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Hold" and an average price target of $25.33.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.